The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.
Megan Kilkeary, PharmD
Advertisement
Articles by Megan Kilkeary, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Stigma to Breakthrough: Psychedelic Medicine
2
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
3
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
4
How Pharmacy and Public Health Partner to Combat Infectious Diseases
5
